Jenny Campbell, MD
Allergy & Immunology · Rogers, ARNPI 1861607368
Payments from drug & device makers
Across 724 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$1K
- Genentech USA, Inc.$1K
- GSK$1K
- CSL Behring$1K
- Takeda Pharmaceuticals U.S.A., Inc.$803
- plus $5K from 31 others
What the payments were for
- Consulting fees$390%
- Food & beverage$12,26696%
- Education$4534%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $1,557 |
| Sanofi | 68 | $1,490 |
| Genentech USA, Inc. | 72 | $1,357 |
| GSK | 115 | $1,140 |
| CSL Behring | 87 | $1,097 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $803 |
| Regeneron Healthcare Solutions, Inc. | 22 | $578 |
| Grifols USA, LLC | 28 | $554 |
| Pfizer | 43 | $533 |
| Sanofi-aventis U.S. LLC | 11 | $457 |
| Amgen | 21 | $412 |
| ARS Pharmaceuticals Operations, Inc. | 15 | $397 |
| Novartis | 27 | $396 |
| Shire North American Group Inc | 27 | $387 |
| Pharming Healthcare, Inc. | 11 | $315 |
| Octapharma USA, Inc. | 8 | $242 |
| Kaleo, Inc. | 12 | $192 |
| Biocryst US Sales Co., LLC | 12 | $185 |
| AbbVie(2 entities) | 6 | $109 |
| Boehringer Ingelheim | 6 | $86 |
| Greer Laboratories, Inc. | 2 | $56 |
| ADMA Biomanufacturing LLC | 3 | $56 |
| Lilly USA, LLC | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Galderma Laboratories, L.p. | 2 | $37 |
| GC Biopharma USA, Inc. | 2 | $31 |
| Organon | 4 | $29 |
| Insmed, Inc. | 1 | $24 |
| Hospira, Inc. | 1 | $24 |
| Ionis Pharmaceuticals, Inc. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Covis Pharma GmbH | 1 | $17 |
| Bio Products Laboratory USA, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,757 in reported general payments places this provider in the 80th percentile of 26 allergy & immunology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 20 | $74,136 |
| XolairOmalizumab | 22 | $58,721 |
| NucalaMepolizumab | 11 | $47,110 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $8,960 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,877 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,752 |
| Epinephrine | 22 | $5,030 |
| Azelastine Hcl | 98 | $2,515 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,277 |
| Montelukast Sodium | 49 | $553 |
| Fluticasone Propionate | 48 | $459 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $326 |
| Ipratropium Bromide | 13 | $298 |
| Azithromycin | 20 | $200 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $1,140 | $60,73933 claims |
| AstraZenecaBreztri Aerosphere | $1,557 | $8,96012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 26 allergy & immunology providers in Arkansas.
Other allergy & immunology in Rogers
- Curtis HedbergRogers$11K
- Adesua WejinyaRogers$10K
- Megan PattersonRogers$4K
- Karl SitzLittle Rock$1.9M
- Anil BadhwarSearcy$499K
- Blake ScheerLittle Rock$81K
- Jim IngramLittle Rock$62K
- Stacy GriffinLittle Rock$10K
- Ashley StonerLittle Rock$7K
- Kim JacksonLittle Rock$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.